Cantor Fitzgerald began coverage on shares of Summit Therapeutics (NASDAQ:SMMT – Free Report) in a research report sent to investors on Friday, Marketbeat Ratings reports. The brokerage issued an ...

Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) have been assigned an average rating of “Moderate Buy” ...

PD-1, PD-L1, and VEGF inhibitors have been approved for over 50 indications in addition to NSCLC. Summit CEO Maky Zanganeh ...

Shares of Summit Therapeutics (NASDAQ:SMMT) gained in the premarket on Friday after Cantor Fitzgerald became the latest to ...

Summit Therapeutics (NASDAQ: SMMT) has been one of the hottest stocks to own over the past 12 months, with its valuation ...

Summit Therapeutics (SMMT – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Eric Schmidt FCA today.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Cantor Fitzgerald initiated coverage of Summit Therapeutics (SMMT) with an Overweight rating. The firm views shares as 67% undervalued, the ...

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal ...

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the ...

Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined ...

In this article, we are going to take a look at where Summit Therapeutics Inc. (NASDAQ:SMMT) stands against other best growth stocks to invest in according to analysts. Companies experiencing ...